Phase 2
N=161
Pre-operative Tamsulosin and Time to Spontaneous Void After Hysterectomy
Urinary Retention Postoperative
Bottom Line
View on ClinicalTrials.gov: NCT04859660 ↗Enrolled (actual)
161
Serious AEs
1.9%
Results posted
Feb 2024
Primary outcome: Primary: Time to Spontaneous Void — 1.63; 1.42 hours
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Tamsulosin (Drug); Placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- University of Arizona
- Primary completion
- Jun 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Time to Spontaneous Void |
1.63; 1.42 | — |
| SECONDARY Time to Discharge From the Post-anesthesia Care Unit |
2.4; 2.6 | — |
Summary
The aim of this study is to determine if a one time dose of tamsulosin given pre-operatively decreases the time to void and the time to discharge after minimally invasive hysterectomy.
Eligibility Criteria
Inclusion Criteria
- Women 18-80 undergoing outpatient minimally invasive hysterectomy
Exclusion Criteria
- Inability to provide informed consent
- Bladder malignancy
- Intra-operative bladder or ureteral injury; anticipated prolonged bladder catheterization
- Plan for sling or anterior repair
Data sourced from ClinicalTrials.gov (NCT04859660). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.